Literature DB >> 26964817

Virtual screening studies to identify novel inhibitors for Sigma F protein of Mycobacterium tuberculosis.

Kiran Kumar Mustyala1, Vasavi Malkhed1, Venkataramana Reddy Chittireddy2, Uma Vuruputuri3.   

Abstract

Tuberculosis (TB) is one of the oldest threats to public health. TB is caused by the pathogen Mycobacterium tuberculosis (MTB). The Sigma factors are essential for the survival of MTB. The Sigma factor Sigma F (SigF) regulates genes expression under stress conditions. The SigF binds to RNA polymerase and forms a holoenzyme, which initiates the transcription of various genes. The Usfx, an anti-SigF protein, binds to SigF and alters the transcription initiation and gene expression. In the present work, virtual screening studies are taken up to identify the interactions between SigF and small molecular inhibitors which can inhibit the formation of holoenzyme. The studies reveal that ARG 104 and ARG 224 amino acid residues of SigF protein are forming important binding interactions with the ligands. The in silico ADME properties for the ligand data set are calculated to check the druggability of the molecules.
Copyright © 2015 Asian African Society for Mycobacteriology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Docking; Mycobacterium tuberculosis; Sigma factor F protein; Virtual screening

Mesh:

Substances:

Year:  2015        PMID: 26964817     DOI: 10.1016/j.ijmyco.2015.05.013

Source DB:  PubMed          Journal:  Int J Mycobacteriol        ISSN: 2212-5531


  2 in total

Review 1.  Molecular Dynamic Simulations and Molecular Docking as a Potential Way for Designed New Inhibitor Drug without Resistance.

Authors:  Jafar Aghajani; Poopak Farnia; Parissa Farnia; Jalaledin Ghanavi; Ali Akbar Velayati
Journal:  Tanaffos       Date:  2022-01

2.  In silico docking and molecular dynamics simulation of 3-dehydroquinate synthase (DHQS) from Mycobacterium tuberculosis.

Authors:  Mustafa Alhaji Isa; Rita Singh Majumdhar; Shazia Haider
Journal:  J Mol Model       Date:  2018-05-11       Impact factor: 1.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.